Leo H. Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Leo H. Wang has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
Rabi Tawil
University of Rochester Medical Center, Rochester, NY, USA
6 shared publicationsKaty Eichinger
University of Rochester Medical Center, Rochester, NY, USA
5 shared publicationsLeann Lewis
University of Rochester Medical Center, Rochester, NY, USA
5 shared publicationsBakri Elsheikh
The Ohio State University, Columbus, OH, USA
4 shared publicationsMichaela Walker
University of Kansas Medical Center, KS City, KS, USA
4 shared publications- Doris G. Leung
Kennedy Krieger Institute
3 shared publications
Latest Publications
- 11 September 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 68, 107423
Clinical associations of pain in an international facioscapulohumeral muscular dystrophy cohort
- 11 September 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 68, 107423
Clinical associations of pain in an international facioscapulohumeral muscular dystrophy cohort
- 22 May 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 64, 106459
Quantitative whole-body MRI in FSHD: assessing systemic involvement and future directions
- 22 May 2026
- Published by Elsevier in Neuromuscular Disorders
- Vol. 64, 106459
Quantitative whole-body MRI in FSHD: assessing systemic involvement and future directions
- Open Access
- 22 February 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (6) , 1545-1554
Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy
Objective: Targeted therapies for facioscapulohumeral muscular dystrophy (FSHD) are progressing through clinical trials. Electrical impedance myography (EIM) provides a noninvasive biomarker of muscle composition that may be valuable especially in early phase trials. This study evaluated EIM data from a multicenter FSHD cohort over 24 months. Methods: Adult patients with FSHD at 8 sites underwent EIM in 6 muscles bilaterally (deltoid, biceps, triceps, vastus lateralis, tibialis anterior, and medial gastrocnemius). EIM outcomes phase and reactance (50 and 100 kHz [kilohertz] frequencies) and 50 of 211 kHz phase ratio were evaluated for reliability, correlations with clinical measures, and sensitivity to change. Results: One hundred fifty‐seven patients (53% male patients) were included. Test–retest reliability was excellent for all EIM outcomes (intraclass correlation coefficient [ICC] ≥0.94). Phase outcomes strongly correlated with the FSHD‐composite outcome measure (FSHD‐COM; r ≤ −0.69) and Motor Function Measure Domain 1 (MFM1; r ≥ 0.75); reactance outcomes exhibited moderate correlations with the FSHD‐COM ( r ≥ –0.41) and MFM1 ( r ≤ 0.44). Mean declines in phase and phase ratio were apparent at 12 months (eg, –0.25, 95% confidence interval [CI] = –0.45 to –0.05 at 50 kHz), and further progressed through 24 months (–0.66, 95% CI = –0.92 to –0.40] at 50 kHz and –0.65 [95% CI = –0.87 to –0.44] at 100 kHz; both p < 0.0001). Reactance changes were smaller and not significant: –0.21 (95% CI = –0.44 to 0.02) at 50 kHz and –0.13 (95% CI = –0.35 to 0.10) at 100 kHz. Interpretation: EIM phase outcomes are reliable, valid, and sensitive to change over 12 to 24 months, supporting their potential utility as biomarkers in FSHD clinical trials. ANN NEUROL 2026;99:1545–1554
- 22 February 2026
- Published by Wiley in Annals of Neurology
- Vol. 99 (6) , 1545-1554
Open AccessElectrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy
Objective: Targeted therapies for facioscapulohumeral muscular dystrophy (FSHD) are progressing through clinical trials. Electrical impedance myography (EIM) provides a noninvasive biomarker of muscle composition that may be valuable especially in early phase trials. This study evaluated EIM data from a multicenter FSHD cohort over 24 months. Methods: Adult patients with FSHD at 8 sites underwent EIM in 6 muscles bilaterally (deltoid, biceps, triceps, vastus lateralis, tibialis anterior, and medial gastrocnemius). EIM outcomes phase and reactance (50 and 100 kHz [kilohertz] frequencies) and 50 of 211 kHz phase ratio were evaluated for reliability, correlations with clinical measures, and sensitivity to change. Results: One hundred fifty‐seven patients (53% male patients) were included. Test–retest reliability was excellent for all EIM outcomes (intraclass correlation coefficient [ICC] ≥0.94). Phase outcomes strongly correlated with the FSHD‐composite outcome measure (FSHD‐COM; r ≤ −0.69) and Motor Function Measure Domain 1 (MFM1; r ≥ 0.75); reactance outcomes exhibited moderate correlations with the FSHD‐COM ( r ≥ –0.41) and MFM1 ( r ≤ 0.44). Mean declines in phase and phase ratio were apparent at 12 months (eg, –0.25, 95% confidence interval [CI] = –0.45 to –0.05 at 50 kHz), and further progressed through 24 months (–0.66, 95% CI = –0.92 to –0.40] at 50 kHz and –0.65 [95% CI = –0.87 to –0.44] at 100 kHz; both p < 0.0001). Reactance changes were smaller and not significant: –0.21 (95% CI = –0.44 to 0.02) at 50 kHz and –0.13 (95% CI = –0.35 to 0.10) at 100 kHz. Interpretation: EIM phase outcomes are reliable, valid, and sensitive to change over 12 to 24 months, supporting their potential utility as biomarkers in FSHD clinical trials. ANN NEUROL 2026;99:1545–1554
- Top Cited PapersOpen Access
- 6 February 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (5) , 1049-1064
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study
Background: Losmapimod is an orally administered small molecule and selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor able to reduce aberrant expression of DUX4 in vitro and thereby potentially slowing disease progression in patients with facioscapulohumeral muscular dystrophy (FSHD). Objective: This global, randomized, placebo-controlled, double-blind phase 3 study in patients with FSHD1 and FSHD2 examined the efficacy and safety of losmapimod over a 48-week treatment period compared to placebo (NCT05397470, EUDRACT 2022-000389-16). Methods: The primary endpoint was change in quantification of reachable workspace (RWS) expressed as relative surface area (RSA). Other endpoints included measures of muscle composition (fat content and lean muscle) using magnetic resonance imaging (MRI), muscle strength using quantitative dynamometry, and quality of life measures. Results: 130 participants received losmapimod and 130 participants received placebo, with 252 participants completing the 48-week treatment period. There were no statistically significant differences between groups in change in RSA and all secondary efficacy endpoints from baseline to Week 48. Losmapimod treatment was well-tolerated, and most adverse events were mild. Conclusions: Losmapimod was generally well tolerated with a favorable safety profile at a dose of 15 mg twice daily. Although none of the efficacy endpoints were met, study design and data from the study may inform future studies of FSHD therapies.
- 6 February 2026
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (5) , 1049-1064
Top Cited PapersOpen AccessA randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study
Background: Losmapimod is an orally administered small molecule and selective p38α/β mitogen-activated protein kinase (MAPK) inhibitor able to reduce aberrant expression of DUX4 in vitro and thereby potentially slowing disease progression in patients with facioscapulohumeral muscular dystrophy (FSHD). Objective: This global, randomized, placebo-controlled, double-blind phase 3 study in patients with FSHD1 and FSHD2 examined the efficacy and safety of losmapimod over a 48-week treatment period compared to placebo (NCT05397470, EUDRACT 2022-000389-16). Methods: The primary endpoint was change in quantification of reachable workspace (RWS) expressed as relative surface area (RSA). Other endpoints included measures of muscle composition (fat content and lean muscle) using magnetic resonance imaging (MRI), muscle strength using quantitative dynamometry, and quality of life measures. Results: 130 participants received losmapimod and 130 participants received placebo, with 252 participants completing the 48-week treatment period. There were no statistically significant differences between groups in change in RSA and all secondary efficacy endpoints from baseline to Week 48. Losmapimod treatment was well-tolerated, and most adverse events were mild. Conclusions: Losmapimod was generally well tolerated with a favorable safety profile at a dose of 15 mg twice daily. Although none of the efficacy endpoints were met, study design and data from the study may inform future studies of FSHD therapies.
- Open Access
- 8 September 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (3) , 264-273
Electrical impedance myography captures features of muscle structure measured by MRI and transcriptomic analysis in facioscapulohumeral muscular dystrophy
Background: Electrical impedance myography (EIM) has been proposed as an efficient, non-invasive biomarker of muscle composition in facioscapulohumeral muscular dystrophy (FSHD). Objective: We investigate whether EIM parameters are associated with muscle structure measured by magnetic resonance imaging (MRI), muscle histology, and transcriptomic analysis as well as strength at the individual leg muscle level. Methods: We performed a multi-center cross-sectional study enrolling 33 patients with FSHD. EIM measurements were recorded from bilateral vastus lateralis, tibialis anterior (TA), and medial gastrocnemius muscles and compared to quantitative muscle volume measures by MRI as well as knee extension and ankle dorsiflexion strength by quantitative muscle testing. EIM measurements of the bilateral TA were further compared to histology and transcriptomic analysis (RNAseq) of muscle and fat content. Results: EIM phase at multiple frequencies was positively associated to the amount of muscle measured by MRI (ρ = 0.48 to 0.70, p ≤ 0.001) and negatively associated to the amount of fat replacement of muscle (ρ = −0.53 to −0.73, p ≤ 0.001). EIM phase of the vastus lateralis and TA was positively associated with knee extension and ankle dorsiflexion strength normalized to age and sex (ρ = 0.45 to 0.60, p < 0.0001). The bilateral TA muscles were analyzed at the histopathological and molecular (transcriptomic) levels and showed that EIM phase was positively associated with amount of muscle (ρ = 0.33 to 0.35, p < .01) and negatively associated with amount of fat (ρ = −0.36 to −0.56, p < .001) by transcriptomic analysis. Conclusions: This study supports the hypothesis that the amount and quality of muscle tissue as assessed by EIM is associated with the amount and quality of muscle tissues as assessed by MRI and muscle biopsy, with all measures ultimately being strongly associated with muscle strength. These data provide further convergent validity for the use of EIM as a potential non-invasive biomarker to assess muscle health in FSHD.
- 8 September 2025
- Published by SAGE Publications in Journal of Neuromuscular Diseases
- Vol. 13 (3) , 264-273
Open AccessElectrical impedance myography captures features of muscle structure measured by MRI and transcriptomic analysis in facioscapulohumeral muscular dystrophy
Background: Electrical impedance myography (EIM) has been proposed as an efficient, non-invasive biomarker of muscle composition in facioscapulohumeral muscular dystrophy (FSHD). Objective: We investigate whether EIM parameters are associated with muscle structure measured by magnetic resonance imaging (MRI), muscle histology, and transcriptomic analysis as well as strength at the individual leg muscle level. Methods: We performed a multi-center cross-sectional study enrolling 33 patients with FSHD. EIM measurements were recorded from bilateral vastus lateralis, tibialis anterior (TA), and medial gastrocnemius muscles and compared to quantitative muscle volume measures by MRI as well as knee extension and ankle dorsiflexion strength by quantitative muscle testing. EIM measurements of the bilateral TA were further compared to histology and transcriptomic analysis (RNAseq) of muscle and fat content. Results: EIM phase at multiple frequencies was positively associated to the amount of muscle measured by MRI (ρ = 0.48 to 0.70, p ≤ 0.001) and negatively associated to the amount of fat replacement of muscle (ρ = −0.53 to −0.73, p ≤ 0.001). EIM phase of the vastus lateralis and TA was positively associated with knee extension and ankle dorsiflexion strength normalized to age and sex (ρ = 0.45 to 0.60, p < 0.0001). The bilateral TA muscles were analyzed at the histopathological and molecular (transcriptomic) levels and showed that EIM phase was positively associated with amount of muscle (ρ = 0.33 to 0.35, p < .01) and negatively associated with amount of fat (ρ = −0.36 to −0.56, p < .001) by transcriptomic analysis. Conclusions: This study supports the hypothesis that the amount and quality of muscle tissue as assessed by EIM is associated with the amount and quality of muscle tissues as assessed by MRI and muscle biopsy, with all measures ultimately being strongly associated with muscle strength. These data provide further convergent validity for the use of EIM as a potential non-invasive biomarker to assess muscle health in FSHD.
- 27 January 2025
- Published by Elsevier in Neuromuscular Disorders
- Vol. 48, 105279
Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophy
- 27 January 2025
- Published by Elsevier in Neuromuscular Disorders
- Vol. 48, 105279
Strength and functional correlates of reachable workspace in facioscapulohumeral muscular dystrophy
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 25 (3) , 115-121
Relationship Between Hand Function and Handheld Ultrasound Imaging in Inclusion Body Myositis
Objective: Ultrasound studies in inclusion body myositis (IBM) have reported a characteristic pattern of increased echointensity in the flexor digitorum profundus (FDP) with relative sparing of the flexor carpi ulnaris (FCU). We examined the relationship between echointensity of the FDP and FCU muscles and hand strength or patient-reported outcomes (PROs). Methods: A total of 15 patients with IBM were recruited. Ultrasound images of the FDP and FCU muscles were obtained by a point-of-care ultrasound and graded using the modified Heckmatt score. Hand grip and neutral pinch strength were measured by dynamometry. PROs were assessed by the IBM Upper Extremity Function Scale. Results: FDP and/or FCU modified Heckmatt score showed a significant relationship with grip, neutral pinch strength, and PROs. Conclusions: Point-of-care ultrasound examination of the forearm may serve as an extension of the neuromuscular examination. The semi-qualitative echointensity rating based on modified Heckmatt score seems to correlate well with the objective strength measurement and PROs.
- 1 March 2024
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 25 (3) , 115-121
Relationship Between Hand Function and Handheld Ultrasound Imaging in Inclusion Body Myositis
Objective: Ultrasound studies in inclusion body myositis (IBM) have reported a characteristic pattern of increased echointensity in the flexor digitorum profundus (FDP) with relative sparing of the flexor carpi ulnaris (FCU). We examined the relationship between echointensity of the FDP and FCU muscles and hand strength or patient-reported outcomes (PROs). Methods: A total of 15 patients with IBM were recruited. Ultrasound images of the FDP and FCU muscles were obtained by a point-of-care ultrasound and graded using the modified Heckmatt score. Hand grip and neutral pinch strength were measured by dynamometry. PROs were assessed by the IBM Upper Extremity Function Scale. Results: FDP and/or FCU modified Heckmatt score showed a significant relationship with grip, neutral pinch strength, and PROs. Conclusions: Point-of-care ultrasound examination of the forearm may serve as an extension of the neuromuscular examination. The semi-qualitative echointensity rating based on modified Heckmatt score seems to correlate well with the objective strength measurement and PROs.
- Open Access
- 7 February 2023
- Published by The University of Kansas in RRNMF Neuromuscular Journal
- Vol. 4 (1) , 27-31
A novel DOK7 mutation causing limb-girdle congenital myasthenic syndrome
We report a case series of 5 Latino patients with limb-girdle pattern weakness, four patients are sisters, with one patient unrelated. Repetitive nerve stimulation showed a significant decrement in all cases. Targeted genetic testing for congenital myasthenic syndromes demonstrated a known DOK7 pathogenic mutation in each case, and in all five cases also revealed a novel DOK7 missense mutation in exon 7 with c.94G>A; providing strong evidence this mutation is pathogenic. DOK7-related congenital myasthenic syndrome often lacks oculobulbar involvement, and may present with limb-girdle weakness, mimicking limb-girdle muscular dystrophy.
- 7 February 2023
- Published by The University of Kansas in RRNMF Neuromuscular Journal
- Vol. 4 (1) , 27-31
Open AccessA novel DOK7 mutation causing limb-girdle congenital myasthenic syndrome
We report a case series of 5 Latino patients with limb-girdle pattern weakness, four patients are sisters, with one patient unrelated. Repetitive nerve stimulation showed a significant decrement in all cases. Targeted genetic testing for congenital myasthenic syndromes demonstrated a known DOK7 pathogenic mutation in each case, and in all five cases also revealed a novel DOK7 missense mutation in exon 7 with c.94G>A; providing strong evidence this mutation is pathogenic. DOK7-related congenital myasthenic syndrome often lacks oculobulbar involvement, and may present with limb-girdle weakness, mimicking limb-girdle muscular dystrophy.
- Open Access
- 17 December 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (11) , 1821-1829
Elevated plasma complement components in facioscapulohumeral dystrophy
Advances in understanding the pathophysiology of facioscapulohumeral dystrophy (FSHD) have led to several therapeutic approaches entering clinical trials and an increased need to develop biomarkers of disease activity and progression. Multiple prior studies have shown early elevation of RNAs encoding components of the complement pathways and relatively widespread activated complement complexes by immunodetection in FSHD muscle. The current study tested plasma from two independent cohorts of FSHD and control subjects and found elevated complement components in both FSHD cohorts. Combining subjects from both cohorts identified complement factors that best distinguished FSHD and controls. Within the FSHD group, a subset of subjects showed elevation in multiple complement components. Together these findings suggest the need for future studies to determine whether measurements of complement activation can be used as a non-invasive measurement of FSHD disease activity, progression and/or response to therapies. In addition, with the ongoing expansion of complement therapeutic approaches, consideration for precision-based targeting of this pathway is appropriate.
- 17 December 2021
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (11) , 1821-1829
Open AccessElevated plasma complement components in facioscapulohumeral dystrophy
Advances in understanding the pathophysiology of facioscapulohumeral dystrophy (FSHD) have led to several therapeutic approaches entering clinical trials and an increased need to develop biomarkers of disease activity and progression. Multiple prior studies have shown early elevation of RNAs encoding components of the complement pathways and relatively widespread activated complement complexes by immunodetection in FSHD muscle. The current study tested plasma from two independent cohorts of FSHD and control subjects and found elevated complement components in both FSHD cohorts. Combining subjects from both cohorts identified complement factors that best distinguished FSHD and controls. Within the FSHD group, a subset of subjects showed elevation in multiple complement components. Together these findings suggest the need for future studies to determine whether measurements of complement activation can be used as a non-invasive measurement of FSHD disease activity, progression and/or response to therapies. In addition, with the ongoing expansion of complement therapeutic approaches, consideration for precision-based targeting of this pathway is appropriate.